ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Nektar Therapeutics

Nektar Therapeutics (NKTR)

0.9342
0.0491
(5.55%)
At close: March 28 04:00PM
0.92
0.0349
( 3.94% )
After Hours: 06:03PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.92
Bid
0.9001
Ask
0.922
Volume
1,315,948
0.8626 Day's Range 0.94
0.4126 52 Week Range 1.12
Market Cap
Previous Close
0.8851
Open
0.88
Last Trade Time
18:03:44
Financial Volume
$ 1,188,550
VWAP
0.903189
Average Volume (3m)
1,633,210
Shares Outstanding
183,617,817
Dividend Yield
-
PE Ratio
-0.63
Earnings Per Share (EPS)
-1.5
Revenue
90.12M
Net Profit
-276.06M

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. The company has additional operations facilities in Huntsville, Alabama... Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. The company has additional operations facilities in Huntsville, Alabama, and Hyderabad, India. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Nektar Therapeutics is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NKTR. The last closing price for Nektar Therapeutics was $0.89. Over the last year, Nektar Therapeutics shares have traded in a share price range of $ 0.4126 to $ 1.12.

Nektar Therapeutics currently has 183,617,817 shares outstanding. The market capitalization of Nektar Therapeutics is $172.60 million. Nektar Therapeutics has a price to earnings ratio (PE ratio) of -0.63.

NKTR Latest News

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference PR Newswire SAN FRANCISCO, March 22, 2024 SAN FRANCISCO, March 22, 2024...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

FYfalse0000906709P3Y130000906709us-gaap:FacilityClosingMember2023-12-310000906709nktr:TwoThousandTwentyTwoAndTwoThousandTwentyThreeRestructuringPlansMember2023-01-012023-03-310000906709nktr:TwoThou...

Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata PR Newswire SAN FRANCISCO, March 5, 2024...

Form 8-K - Current report

false 0000906709 0000906709 2024-03-04 2024-03-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED...

Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results

Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results PR Newswire SAN FRANCISCO, March 4, 2024 SAN FRANCISCO, March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq:...

Form 8-K - Current report

NASDAQ false 0000906709 0000906709 2024-03-04 2024-03-04     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT...

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX PR Newswire SAN FRANCISCO, March 4, 2024 SAN FRANCISCO, March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq:...

Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference

Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference PR Newswire SAN FRANCISCO, Feb. 27, 2024 SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq:...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0070.7667031763420.9130.940.8411934990.89491042CS
40.1824.32432432430.741.080.701525694060.88628212CS
120.359964.25638278880.56011.080.4816332100.77418102CS
260.323854.31063401540.59621.080.412615880540.633482CS
520.14618.86304909560.7741.120.412636977200.75767537CS
156-18.93-95.365239294719.8520.90.412626761664.0958788CS
260-30.92-97.110552763831.84370.412623035629.54716175CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
QLIQilian International Holding Group Ltd
$ 1.04
(50.75%)
2.73M
GRTXGalera Therapeutics Inc
$ 0.1732
(23.71%)
965.43k
MEDPMedpace Holdings Inc
$ 480.00
(18.77%)
1.38k
SBFMSunshine Biopharma Inc
$ 0.0715
(18.18%)
24.13M
JSPRWJasper Therapeutics Inc
$ 0.2147
(17.97%)
600
XTKGX3 Holdings Company Ltd
$ 0.6499
(-34.36%)
1.23M
NVVENuvve Holding Corporation
$ 0.805
(-26.82%)
112.2k
NDRAENDRA Life Sciences Inc
$ 0.455
(-21.55%)
123.87k
MVLAMovella Holdings Inc
$ 0.0501
(-19.71%)
489.27k
KYCHKeyarch Acquisition Corporation
$ 10.06
(-18.21%)
9k
SBFMSunshine Biopharma Inc
$ 0.0715
(18.18%)
24.13M
CRKNCrown Electrokinetics Corporation
$ 0.0621
(3.67%)
6.57M
AAPLApple Inc
$ 171.44
(-0.02%)
3.54M
JAGXJaguar Health Inc
$ 0.08705
(-3.17%)
3.01M
CISSC3is Inc
$ 0.0342
(-1.72%)
2.88M

NKTR Discussion

View Posts
glenn1919 glenn1919 3 weeks ago
NKTR..............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 3 weeks ago
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
👍️0
glenn1919 glenn1919 4 weeks ago
NKTR.......................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 4 weeks ago
NKTR 10Q March 4
👍️0
Monksdream Monksdream 5 months ago
NKTR new 52 week low
👍️0
Monksdream Monksdream 6 months ago
NKTR new 52 week low
👍️0
seve333 seve333 6 months ago
Stock is in the toilet again they need an actual settlement from LLY go get the stock moving and so far crickets.
👍️0
sc00pnDump sc00pnDump 6 months ago
Nice stock options 0.68 @ 85,000 shares
👍️0
81vette 81vette 8 months ago
Holding up amazingly well,might continue up
👍️0
Invest-in-America Invest-in-America 8 months ago
NKTR: Now suing Eli Lilly, in conjunction with today's earlier (Dermatitis) news package.
👍️0
Invest-in-America Invest-in-America 8 months ago
NKTR: This one ain't over until the FAT PHARMACISTS sing!!
👍️0
Invest-in-America Invest-in-America 8 months ago
NKTR: Huge numbers of Peeps MISSED your brilliant pick here today, Dude!!! (Talk about 'easy money'!!)
👍️0
AJ Freely AJ Freely 8 months ago
$NKTR - 👆Up 15.8% Pre-Market/ Current Price $0.61
Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in '22 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company
👍️0
The Night Stalker The Night Stalker 9 months ago
cheap
👍️0
The Night Stalker The Night Stalker 9 months ago
cheap
👍️0
DavidTrader DavidTrader 1 year ago
pincher chart on the daily and weekly, I think this could easily run to $1.50
👍️0
Lilman72003 Lilman72003 1 year ago
Hmmm just crickets around here, I don’t mind arriving early to the party
👍️0
DewDiligence DewDiligence 2 years ago
NKTR -24%/AH on_termination_of Bempeg program following phase-3 failures in RCC and bladder cancer:

https://finance.yahoo.com/news/nektar-bristol-myers-squibb-announce-203000621.html Nektar Therapeutics and Bristol Myers Squibb (NYSE: BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo. These studies and all other ongoing studies in the program will be discontinued. Bempeg previously failed in a phase-3 trial in combination with Opdivo in melanoma (#msg-168191364), so today’s news is three strikes and you’re out!

Rarely has a cancer drug failed so utterly and completely to live up to initial expectations (#msg-138532013). NKTR’s share price is down 96%(!) from its 2018 high.
👍️0
Frankestin Frankestin 2 years ago
Ouch Ouch
how it hurts here!
I don't even see a reason to hope it goes up!
How much cash do they have?
But that's enough until the end of 2024 if that's okay ...
THE MANAGER OF NEKTAR THERAPEUTICS SAYS TO PREPARE A PLAN THAT HAS THE OBJECTIVE OF ESTABLISHING THE MINIMUM CASH TRACK UNTIL AT LEAST 2024 - CONF. CALL
As the drug fails to meet any of its goals, Nektar said he would consider curbing his cash spending, which was about $ 800 million at the end of December.


Last week, brokerage agency Oppenheimer estimated that worldwide un-risk-adjusted bempegaldesleukin sales could reach $ 3.7 billion in 2038. (news)

I know of one recently approved that will do 3B by 2026
👍️0
DewDiligence DewDiligence 2 years ago
NKTR’s Bempeg fails as addend to Opdivo in first-line melanoma:

https://finance.yahoo.com/news/bristol-myers-squibb-nektar-announce-105900961.html Bristol Myers Squibb and Nektar Therapeutics today announced an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo (nivolumab) compared to Opdivo monotherapy as a first-line treatment for previously untreated unresectable or metastatic melanoma. Following a review of the study for efficacy and safety by an independent Data Monitoring Committee (DMC), Bristol Myers Squibb and Nektar were informed that the study did not meet the primary endpoints of progression-free survival (PFS) and objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR). The DMC notified the companies that the third primary endpoint of overall survival (OS) did not meet statistical significance at the first interim analysis.

Given there was no additional clinical benefit in the doublet therapy arm compared to the monotherapy arm for the primary endpoints of PFS and ORR, and based on the data reviewed by the DMC, the companies have decided to unblind the trial and to perform no additional analyses for the OS endpoint.

Additionally, based on the results from PIVOT IO-001, the companies have also made the decision to discontinue enrollment and unblind the ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma.
👍️0
DewDiligence DewDiligence 3 years ago
NKTR +18% on clinical-trial_collaboration_testing Bempeg+Keytruda in_H&N_cancer:

https://finance.yahoo.com/news/nektar-announces-agreement-phase-2-130000352.html

NKTR is receiving no cash from MRK—only free drug for use in the trial. Rather, unding for the trial is being provided by NKTR’s financing deal with SJC Pharma (https://finance.yahoo.com/news/nektar-announces-collaboration-sfj-pharmaceuticals-125900283.html ).

Note that the 3-year PD-(L)1 exclusivity period of the BMY/NKTR collaboration, which was announced on 2/14/18, has now expired, enabling NKTR to test Bempeg with any PD-(L)1 agent of its choosing.

p.s. Even after today’s pop, NKTR’s share price is down about 70% from the day of the BMY announcement three years ago.
👍️0
ClayTrader ClayTrader 4 years ago
* * $NKTR Video Chart 01-15-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
DewDiligence DewDiligence 4 years ago
Comments on the JPM webcast: #msg-153299506.
👍️0
DewDiligence DewDiligence 4 years ago
We talk about NKTR a little on #board-1418.
👍️0
Sluicebox Sluicebox 4 years ago
On what board are people discussing Nektar ?
👍️0
czni czni 4 years ago
Yea, bloody taa for !?
I will check back. Those were shot down before I could focus on them. It’s just that one ticker.
A big pharm company is going to buy 11% of a biotech company.
Whatever you do
Find it.
Two day jump could mean over 50% growth before all the old-timers start jumping out because they were holding this in 1912. BC :)
Im an old timer so I can say this.
Dont miss this one!
And please dont let me miss.
I have an entire day on this :(

Once we are free of that, all of the new people will be coming in by Thursday.

Come on people? It’s really important.
👍️0
czni czni 4 years ago
Well if that wasn’t the strangest thing on the planet?

My plan was to research the heck out of this thing and share it with who is on this weekend.

This way we can start Monday ahead of the pac.

There really are only two questions that I would like answers to. This company of course and it’s future and of course what my other message said. Much obliged and whatever I find out, it stays right here.

👍️0
czni czni 4 years ago
I have been doing a lot of studying on this company. I know that we are closer to the 52 week wow than the high. This sector is supposed to be picking up in this company looks pretty decent. What can we expect as far as mergers or stock forecast for 2020? Pretty legitimate not asking for million dollar tickers...

Where are we and where are we going....
👍️0
czni czni 4 years ago
You saw that, yes.
thanks but I do not have a photographic memory unfortunately.

Looks like you were taken down.
Fast!
But we’re smarter than that
👍️0
czni czni 4 years ago
That’s why I love this board. You don’t have to deal with scammers or flippers or anybody trying to feed you a line just to buy end so they can dump. You guys have already been very hospitable. There’s a certain company farmer that is going to buy 11% of a biotech company. If we can find out the ticker symbol on this biotech company,
it’s worth about 180% in the first three days and a bunch more coming after.

Right now the biotech price is very low.

If we can keep it to just us for now The ones here that are interested can get in before the world finds out about it.
Trust me,
I spent four hours digging and digging to find this ticker.

Nobody is leaking it.

Come on guys,
dig a little bit with me.
I promise you it will be worth it!

I put a lot of time in. As soon as I find it I will share on this page. And only this page! It’ll be taken down by Monday so it needs to happen. Everybody takes 15 minutes.

With the experience reading this,
I have no question we can get this ticker symbol.

Monday morning we will be locked and loaded!

Oh yes!
👍️0
czni czni 4 years ago
Hey gang,
Im a quiet holder but have a question driving me crazy!

The MU wait for chips was so Ridiculous even after having this giant to do in Las Vegas.

Do you know the people that paid all around the world to go to Las Vegas just to hear that ticker symbol was not given out at that meeting?

You had to purchase his book in order to get it.

As soon as I dug it up,
I gave it out to everybody.

Now this big Pharma company whoever they are,
are getting ready to purchase 11% of a biotech company.

It has not happened yet but I’m looking for the ticker symbol for the biotech company.

The Pharma company is already out of reach but the biotech company There’s a couple of very important patents making the merger happen quicker.

Does anybody know the biotech company ticker symbol?

I need something that’s going to climb and keep climbing.

On a sidenote,
before my wife finds out I lost just about everything on the stock that should have gone to 50 plus wish i had known they had trouble with their CEO and the CFO having private meetings putting the company under investigation and stopping all Trading for over a month. It trades for 1/10000 of a penny now. I put everything on it!!!

. If you can throw that out to me, you could possibly change my marriage LOL.
Thanks very much and good skill to everyone!
The only job that I have ever had that did not look forward to the weekends!!! Happy hunting!
I dont have pm but please use it if you can. Happy Holidays!

Thanks gang

Sweet Virginia Breeze
👍️0
Clemdane Clemdane 4 years ago
Thinking people are just taking profits today?
👍️0
whytestocks whytestocks 4 years ago
News: $NKTR 2 Stocks That Soared Monday While the Market Slumped

Are you in the holiday spirit yet? Well, obviously the stock market isn't, given its tepid performance on Monday. Most major indexes sagged, with many stocks sinking along with them. Monday's a good day to go positive, though, so I'm going to highlight two stocks that bucked this trend and incr...

Got this from NKTR - 2 Stocks That Soared Monday While the Market Slumped
👍️0
whytestocks whytestocks 4 years ago
News: $NKTR Why Nektar Therapeutics Stock Popped Today

Shares of Nektar Therapeutics (NASDAQ: NKTR) were up 11.4% as of 3:15 p.m. EST on Monday. The biotech presented data Sunday evening at the American Society of Hematology (ASH) annual meeting from a preclinical trial evaluating immunotherapy NKTR-255. Nektar also received a boost from news th...

Read the whole news NKTR - Why Nektar Therapeutics Stock Popped Today
👍️0
whytestocks whytestocks 4 years ago
News: $NKTR Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting

SAN FRANCISCO , Dec. 9, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced three presentations at the 61 st American Society of Hematology (ASH) Annual Meeting & Exposition for its IL-15 agonist and investigational candidate, NKTR-255. Data were presented fr...

In case you are interested NKTR - Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
👍️0
whytestocks whytestocks 4 years ago
News: $NKTR Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology

SAN FRANCISCO , Nov. 10, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced updated results from the first-in-human Phase 1a study of NKTR-358, a novel T regulatory (Treg) cell stimulator in development for the treatment of autoimmune and other chronic inflammato...

Read the whole news NKTR - Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
👍️0
whytestocks whytestocks 4 years ago
News: $NKTR Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN FRANCISCO , Nov. 9, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of five clinical and preclinical data abstracts focused on its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting. New clin...

Got this from NKTR - Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
👍️0
ClayTrader ClayTrader 4 years ago
* * $NKTR Video Chart 10-08-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
behindthebid behindthebid 5 years ago
Everything You Need For Your Premarket Including Nektar

Nektar had some manufacturing issues for its cancer drug, certainly hurting company credibility. Every day there is a Premarket Breakfast post with what's going on, why, gappers and sentiment. Today's Post is at

https://www.behindthebid.com/posts/premarket-breakfast-for-friday-august-9th
👍️0
DewDiligence DewDiligence 5 years ago
NKTR says two production lots of NKTR-214 were substandard—possibly causing the attenuated recent responses in PIVOT-02 compared to the early responses. Ouch.
👍️0
DewDiligence DewDiligence 5 years ago
Hmm…

https://finance.yahoo.com/news/nektar-therapeutics-reports-financial-results-201500243.html Nektar is hosting a conference call with analysts and investors today on which it will discuss quarterly results. On the call, the company will provide a specific update and discussion on its bempegaldesleukin clinical development program, including recent developments related to the manufacturing of bempegaldesleukin. Bempegaldesleukin is f/k/a NKTR-214.

The stock is currently halted. CC at 5pm ET.
👍️0
jondoeuk jondoeuk 5 years ago
A trial in Germany is testing a neoantigen based vaccine (+/- Bempeg) in pts with locally advanced or metastatic melanoma, NSCLC, RCC (clear), UC or squamous cell carcinoma of head and neck, who did not achieve a CR with current standard of care immune checkpoint blockade https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002474-39/DE
👍️0
whytestocks whytestocks 5 years ago
News: $NKTR Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma

SAN FRANCISCO , Aug. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-214) in comb...

Find out more Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
👍️0
DewDiligence DewDiligence 5 years ago
NKTR 4Q18 CC transcript:

https://finance.yahoo.com/news/nektar-therapeutics-nktr-q4-2018-140037448.html
👍️0
jondoeuk jondoeuk 5 years ago
ASCO-SITC Clinical Immuno-Oncology Symposium abstract

Background: NKTR-262 is a novel intratumoral prodrug designed to promote tumor antigen release, an immune stimulatory environment, and antigen presentation. NKTR-214 increases CD8+ T cells and NK cells in the tumor microenvironment. The combination of NKTR-262 with NKTR-214 accesses innate and adaptive immunity to provide an abscopal response and systemic tumor immunity. The Phase 1b/2 REVEAL trial is enrolling.

Methods: In a 3+3 Phase 1 design, pts who are relapsed/refractory to ≥1 CPI receive escalating doses of intratumoral (IT) NKTR-262 followed by combined q3w treatment of IT NKTR-262 and fixed-dose intravenous (IV) NKTR-214 (0.006 mg/kg). Phase 1 will evaluate PK, safety, efficacy, and determine recommended Phase 2 dose. Scans are conducted every 9 wks (± 1 wk). Peripheral blood (PB) and tumor tissue are collected to measure biomarkers of immune activation. In Phase 2 expansion, NKTR-262 + NKTR-214 ± IV nivolumab (360 mg) will be assessed in specific tumor cohorts of IO-naïve and experienced pts.

Results: As of 06 Nov 2018, 11 pts had received at least one cycle of NKTR-262 + NKTR-214 therapy. 7/11 pts were efficacy evaluable with at least one on-treatment scan (4 MEL, 2 SARC, 1 CRC). 2/4 R/R melanoma pts had uPRs with 100% (scan 2) and 40% (scan 1) reductions in target lesions per RECIST 1.1, respectively. Both patients remain on treatment. Two SARC pts had stable disease at scan 1. No pts experienced G3 or higher TRAEs or immune-related adverse events (AEs). Most common G1-2 AEs were transient flu-like symptoms. Gene expression analysis of tumor and PB show dose-dependent induction (4 to 16-fold) of TLR target genes. Consistent with the mechanism of action for NKTR-214, PB flow cytometry shows an average 13-fold increase from baseline in Ki67+ CD8+T cells in 6 pts.

Conclusions: NKTR-262 + NKTR-214 engage the immune activation cascade from local tumor antigen production to anti-tumor T cell response. Initial dose levels of NKTR-262 with fixed-dose NKTR-214 were well-tolerated with early evidence of clinical activity. These data support continued evaluation of the combination +/- nivolumab. Clinical trial information: NCT03435640

https://meetinglibrary.asco.org/record/170420/abstract
👍️0
jondoeuk jondoeuk 5 years ago
Dr. Zalevsky will provide updates on NKTR-214 during the preclinical plenary session at IO360 https://theconferenceforum.org/conferences/immuno-oncology-360/overview/
👍️0
jondoeuk jondoeuk 5 years ago
From this: ''With NKTR-214, a kinetically engineered IL-2 receptor agonist, the B2M knockout cell lines also overcame resistance to PD-1 inhibition and it increased survival significantly in these cell lines.'' https://www.targetedonc.com/conference/sitc-2018/two-rapidfire-abstracts-break-down-biomarkers-of-response-and-resistance
👍️0
DewDiligence DewDiligence 5 years ago
SITC data—Melanoma PIVOT-02 ORR=53%* (20*/38)—24% (9/38) CRs:

PR:
https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-presents-new-clinical-and-preclinical-data

CC slides:
https://t.co/cnESfELNnp

Of the 33 patients with known (pre-treatment) PD-L1 status, ORR was: 43% (6/14) in PD-L1-negative patients; and 68% (13/19) in PD-L1-positive patients.

*One additional responder relative to the SITC abstract, which was 50% (19/38).
👍️0
jondoeuk jondoeuk 5 years ago
I had a few too many. What I should have added is that the reason I don't own more shares is due to 'issues' I have with management. Not long after O'Connor became CEO I sold a number of them.
👍️0
DewDiligence DewDiligence 5 years ago
NKTR 3Q18 results—cash=$2.0B:

https://finance.yahoo.com/news/nektar-therapeutics-reports-financial-results-211000969.html

The previous post is in error regarding the cash balance—please ignore it.
👍️0

Your Recent History

Delayed Upgrade Clock